Erste Asset Management GmbH Has $27.33 Million Stock Position in Regeneron Pharmaceuticals, Inc. $REGN

Erste Asset Management GmbH cut its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 8.7% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 48,736 shares of the biopharmaceutical company’s stock after selling 4,661 shares during the period. Erste Asset Management GmbH’s holdings in Regeneron Pharmaceuticals were worth $27,329,000 as of its most recent SEC filing.

Other hedge funds have also recently added to or reduced their stakes in the company. Brighton Jones LLC increased its stake in shares of Regeneron Pharmaceuticals by 261.8% in the 4th quarter. Brighton Jones LLC now owns 948 shares of the biopharmaceutical company’s stock valued at $675,000 after acquiring an additional 686 shares during the last quarter. Dynamic Technology Lab Private Ltd acquired a new position in Regeneron Pharmaceuticals during the first quarter valued at approximately $226,000. Oppenheimer Asset Management Inc. increased its stake in Regeneron Pharmaceuticals by 32.7% in the second quarter. Oppenheimer Asset Management Inc. now owns 2,608 shares of the biopharmaceutical company’s stock valued at $1,369,000 after purchasing an additional 643 shares in the last quarter. Rossby Financial LCC increased its stake in Regeneron Pharmaceuticals by 25.0% in the second quarter. Rossby Financial LCC now owns 180 shares of the biopharmaceutical company’s stock valued at $94,000 after purchasing an additional 36 shares in the last quarter. Finally, New York Life Investment Management LLC raised its holdings in Regeneron Pharmaceuticals by 0.8% in the second quarter. New York Life Investment Management LLC now owns 14,353 shares of the biopharmaceutical company’s stock worth $7,535,000 after purchasing an additional 113 shares during the period. Institutional investors and hedge funds own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Stock Performance

Shares of Regeneron Pharmaceuticals stock opened at $770.79 on Friday. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.13 and a quick ratio of 3.39. The firm has a market cap of $81.49 billion, a price-to-earnings ratio of 18.55, a price-to-earnings-growth ratio of 2.11 and a beta of 0.40. The stock’s 50-day moving average is $771.32 and its 200-day moving average is $679.14. Regeneron Pharmaceuticals, Inc. has a one year low of $476.49 and a one year high of $821.11.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings data on Friday, January 30th. The biopharmaceutical company reported $11.44 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $10.74 by $0.70. The business had revenue of $3.88 billion during the quarter, compared to the consensus estimate of $3.76 billion. Regeneron Pharmaceuticals had a return on equity of 13.04% and a net margin of 31.41%.Regeneron Pharmaceuticals’s quarterly revenue was up 2.5% on a year-over-year basis. During the same period last year, the company earned $12.07 earnings per share. Equities analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, March 5th. Stockholders of record on Friday, February 20th will be given a $0.94 dividend. This is a boost from Regeneron Pharmaceuticals’s previous quarterly dividend of $0.88. This represents a $3.76 dividend on an annualized basis and a dividend yield of 0.5%. The ex-dividend date of this dividend is Friday, February 20th. Regeneron Pharmaceuticals’s payout ratio is presently 9.05%.

Analyst Ratings Changes

REGN has been the subject of several research analyst reports. Truist Financial decreased their price target on shares of Regeneron Pharmaceuticals from $820.00 to $818.00 and set a “buy” rating for the company in a report on Monday, February 2nd. Cantor Fitzgerald boosted their target price on Regeneron Pharmaceuticals from $740.00 to $800.00 and gave the company an “overweight” rating in a research note on Monday, February 2nd. UBS Group increased their price target on Regeneron Pharmaceuticals from $595.00 to $660.00 and gave the stock a “neutral” rating in a report on Friday, November 7th. BMO Capital Markets raised their price target on Regeneron Pharmaceuticals from $725.00 to $850.00 and gave the stock an “outperform” rating in a research report on Thursday, December 4th. Finally, Bank of America upgraded Regeneron Pharmaceuticals from an “underperform” rating to a “buy” rating and boosted their price objective for the company from $627.00 to $860.00 in a research report on Wednesday, January 7th. Two analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $793.81.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, Director Arthur F. Ryan sold 100 shares of the business’s stock in a transaction dated Monday, February 9th. The shares were sold at an average price of $778.53, for a total transaction of $77,853.00. Following the sale, the director directly owned 17,803 shares of the company’s stock, valued at $13,860,169.59. The trade was a 0.56% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Also, SVP Jason Pitofsky sold 2,036 shares of the stock in a transaction dated Monday, February 9th. The stock was sold at an average price of $778.52, for a total transaction of $1,585,066.72. Following the transaction, the senior vice president owned 4,272 shares of the company’s stock, valued at approximately $3,325,837.44. This represents a 32.28% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders sold 5,274 shares of company stock worth $4,142,738. Company insiders own 7.02% of the company’s stock.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.